文献速递浆细胞疾病

多发性骨髓瘤患者自体干细胞移植后持续3年骨髓及影像学MRD阴性可停止维持治疗

Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma.
PubMed 文献 · Blood · 2025-01-01

这项前瞻性研究评估了52例多发性骨髓瘤患者自体干细胞移植后达到持续3年骨髓及影像学MRD阴性后停止来那度胺维持治疗的转归。停药后中位随访3年,12例(23%)出现MRD阳性并重新开始来那度胺维持治疗,仅4例(7.6%)进展。7年PFS率为90.2%,停药后1年、2年、3年无治疗生存率分别为93.9%、91.6%、75.8%。

要点

  • 持续3年骨髓及影像学MRD阴性后停用来那度胺,仅7.6%患者进展。
  • 停药后23%患者出现MRD阳性,重新开始来那度胺维持治疗。
  • 停药后3年无治疗生存率为75.8%,3年landmark PFS率为92.9%。

核心结论

  • 持续3年骨髓及影像学MRD阴性后停止维持治疗与较低的MRD转阳率和疾病进展率相关。
  • 在现代抗骨髓瘤治疗时代,部分患者可在不损害疾病缓解的情况下保持无治疗状态。

研究设计与样本

  • 前瞻性研究,纳入52例多发性骨髓瘤患者,均在自体干细胞移植后达到持续3年骨髓及影像学MRD阴性并停止来那度胺维持治疗。
  • 停药后出现MRD阳性的患者以相同剂量重新开始来那度胺维持治疗。
  • 从来那度胺停药起中位随访3年。

主要发现

  • 12例(23%)患者出现MRD阳性并重新开始来那度胺维持治疗。
  • 仅4例(7.6%)患者进展,其中3例为生化进展,1例为临床进展。
  • 总体中位PFS未达到,自诊断起7年PFS率为90.2%。
  • 停药后1年、2年、3年无治疗生存率分别为93.9%、91.6%、75.8%。
  • 停药后(研究入组)1年、2年、3年landmark PFS率分别为96.0%、96.0%、92.9%。

关键数值与推荐

  • 年龄、性别、第二次修订的国际分期系统、诱导治疗类型及巩固治疗使用与PFS和TFS效应结局之间均无统计学显著关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Discontinuation of lenalidomide maintenance after autologous stem cell transplantation is a burning question within the multiple myeloma (MM) community, especially after the inclusion of minimal residual disease (MRD) in the disease response criteria. In this prospective study, we evaluated the conversion to MRD positivity, the treatment-free survival (TFS), and the progression-free survival (PFS) in 52 patients with MM who discontinued lenalidomide maintenance after achieving sustained bone marrow and imaging MRD negativity for 3 years. Patients who developed MRD positivity after lenalidomide discontinuation restarted lenalidomide maintenance at the same dose. The median follow-up from lenalidomide discontinuation was 3 years. Overall, 12 (23%) patients obtained MRD positivity and restarted lenalidomide maintenance. Only 4 (7.6%) patients progressed; 3 had a biochemical progression and 1 had a clinical progression. The overall median PFS was not reached, whereas the 7-year PFS from diagnosis was 90.2%. The 1-, 2-, and 3-year TFS rates were 93.9%, 91.6%, and 75.8%, respectively, whereas the 1-, 2-, and 3-year landmark PFS rates from maintenance discontinuation (study entrance) were 96.0%, 96.0%, and 92.9%, respectively. There were no statistically significant associations among age, sex, Second Revision International Staging System, type of induction therapy, and use of consolidation therapy and the effect outcomes of PFS and TFS. We conclude that maintenance discontinuation after 3 years of sustained marrow and imaging MRD negativity is associated with low rates of MRD conversion and progressive disease. Thus, in the era of modern antimyeloma treatments, a subgroup of patients may remain treatment free while in complete remission without jeopardizing disease response.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Terpos E, Malandrakis P, Ntanasis-Stathopoulos I, et al. Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma. Blood. 2025. PMID: 40009496. doi:10.1182/blood.2024027686

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。